Eric Ostertag reaching the end of the line as Poseida chief, will become executive chairman; Alector exec named CEO of Pfizer-backed LNP biotech
→ The Poseida adventure takes another turn as CEO Eric Ostertag dives into the role of executive chairman and CBO Mark Gergen steers the ship starting Feb. 1. Ostertag talked through Poseida’s early proof-of-concept data with its PSMA-targeting CAR-T for prostate cancer patients in August 2021, and the San Diego biotech followed that up by inking a $3.6 billion-plus gene therapy deal with Takeda in October.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.